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Creating a risk model to determine paraaortic lymph node
involvement in endometrial carcinoma
Ahmet Taner TURAN1, Burcu AYKAN YILDIRIM1, Işın ÜREYEN1, Deniz HIZLI2, Mustafa Alper KARALÖK1,
Ömer Lütfi TAPISIZ1, Hakkı Gökhan TULUNAY1, Nurettin BORAN1, Nejat ÖZGÜL1, Mehmet Faruk KÖSE1

Aim: To define a high-risk group for paraaortic (PA) lymph node metastasis among endometrial carcinoma patients.
Materials and methods: Prognostic factors determining PA lymph node metastasis were defined. Using these factors in
different combinations, 14 risk groups were formed. A patient with at least one of these factors was considered as highrisk for PA lymph node metastasis.
Results: This study included 152 patients. Of these patients, 18 had tumors in the PA region. Lymphovascular space
invasion (LVSI) and pelvic lymph node metastasis were independent prognostic factors for PA lymph node involvement.
In the risk modeling system, pelvic lymph node metastasis was an important factor in predicting PA lymph node status,
and in groups where this factor was included for risk modeling, PA lymph node involvement was significantly increased
in high-risk patients. Best results were obtained with the risk group model (group 10) involving cell type, LVSI, serosal
spread, adnexal metastasis, and pelvic lymph node as prognostic factors. In this group sensitivity was 94%, specificity
was 53.7%, and negative and positive predictive values were 98.6% and 21.5%, respectively. According to this model,
52% of all patients were in the high-risk group.
Conclusion: Group 10 seemed to include the guiding properties for a decision on paraaortic lymphadenectomy and it
was possible to reduce unnecessary paraaortic lymphadenectomies by 50%.
Key words: Endometrial cancer, paraaortic lymph node metastasis

Introduction
Endometrial carcinoma has been staged surgically
since 1988 according to International Federation
of Gynecology and Obstetrics (FIGO) criteria.
However, the extent of surgery, whether a
lymphadenectomy should be done or not, and the
extent of lymphadenectomy are controversial points.
Pelvic and paraaortic (PA) lymphadenectomy is
known to increase morbidity and mortality (1,2).
In cases of grade 1 endometrioid tumor with less
than half myometrial invasion and no cervical
invasion or adnexal spread, it is known that this

procedure is not associated with an increase in
survival rates (3). Patients considered as high-risk
for lymph node metastasis undergo both pelvic
and PA lymphadenectomies; however, the extent of
lymphadenectomy is not clearly defined. In selected
patients, is pelvic lymphadenectomy alone enough,
or should PA lymphadenectomy be added? If PA
lymphadenectomy is indicated, where should the
limit of the procedure be, the inferior mesenteric
artery or the left renal vein? If PA lymphadenectomy
is to be a part of the surgery, it needs to be done up to
the level of the renal vein. Mariani et al. showed that
77% of patients with pelvic lymph node metastasis
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also had metastatic lymph nodes superior to the level
of the inferior mesenteric vein and that in more than
half of these patients lymph node metastasis was only
at these sites (4). Other studies also demonstrated
similar results (5,6).
The main point of discussion should be the
necessity of PA-region lymphadenectomy. Under
which surgical circumstances should we add PA
lymphadenectomy to the surgical procedure, and is it
associated with an increase in survival rates? These are
unclear issues. It was shown in multivariate analysis
that pelvic lymph node metastasis, cell type, presence
of lymphovascular space invasion (LVSI), patient
age, tumor grade, depth of myometrial invasion, and
cervical invasion were determining factors for PA
lymph node metastasis (7–12). However, when these
studies are evaluated individually, it can be seen that
one or more of these factors is found to be significant
while the others are not, or vice versa. For example,
in a study by Yokoyama et al., tumor grade and
myometrial invasion were significant risk factors for
PA lymph node metastasis while LVSI was not (11).
For that reason, using only one risk factor to argue
for the necessity of PA lymphadenectomy will lead to
unnecessary morbidity or inadequate treatment.
It is known that in 45%–67% of patients with
pelvic lymph node metastasis, there is tumoral spread
in the PA region (4,5,7,10). Reported rates of isolated
PA lymph node metastasis range between 0% and 8%
(6,8,10–14). It was proposed that routine addition of
PA lymphadenectomy to pelvic lymphadenectomy
was not associated with a significant advantage in
terms of survival (10,15). For these reasons, it seems
rational to define high-risk patients who will benefit
from PA lymphadenectomy and form risk groups.
In our previous study we showed that the risk
model including the existence of pelvic lymph node
metastasis, nonendometrioid cell type, LVSI, adnexal
spread, and serosal involvement could predict PA
metastasis in endometrial carcinoma (16). In the
current study, risk models were created based on the
previous study to predict PA-region metastasis. The
efficiencies of these groups in predicting PA metastasis
were evaluated. We aimed to create risk models
predicting the necessity for PA lymphadenectomy.
1260

Materials and methods
Patients were staged according to FIGO 1988
criteria. We performed surgical staging for patients
whose intraoperative frozen pathology revealed
endometrial tumor with cell types other than
endometrioid adenocarcinoma, tumor grade 2 or 3,
≥1/2 myometrial invasion, and tumor size greater
than 2 cm. Patients diagnosed to have grade 3 tumor
or high-risk cell types preoperatively underwent
surgical staging without intraoperative histologic
evaluation.
In the present study, the data of 152 patients
with a sufficient pathology report who underwent
systematic lymphadenectomy up to the level of the
renal vein with the removal of at least 15 pelvic and
10 PA lymph nodes were analyzed retrospectively.
The incidence of PA lymph node metastasis and
prognostic factors determining metastasis were
determined. The influence of clinicopathologic
factors on PA lymph node metastasis was examined
using the chi-square test. Statistical power of factors
was examined using multivariate logistic regression
analysis and statistical analysis was performed using
SPSS 17.0. The cut-off for statistical significance
was set at P < 0.05. By using different combinations
of these factors, 14 risk groups were formed (Table
1). Statistical results and data from the literature
about prognostic factors determining PA lymph
node metastasis were taken into consideration when
creating these risk groups.
Patients with at least one of the factors used to
define the risk groups were accepted as having high
risk for that model. The strength of risk groups to
predict PA-region lymph node status was analyzed
using sensitivity, specificity, negative predictive value
(NPV), and positive predictive value (PPV).

Results
The mean age of the patients was 57.5 years (range:
35–83) and mean tumor size was 39.3 mm (range:
0–110 mm). Tumor stage ranged between IA and
IVB and 91 (59.9%) patients had stage I tumor.
Pathologic diagnosis was endometrioid-type tumor
in 128 (84.2%) patients. Surgical and pathological
data are shown in detail in Table 2.
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Table 1. Risk groups.
Risk
group

Cell
type

1

+

+

+

+

2

+

+

+

+

Grade DMI

LVSI

CI

3

+

+

+

4

+

+

+

5

+

+

+

+

6

+

+

+

+

7

+

+

+

+

+

+

+

+

+

8

+

9

+

+

Serosal
invasion

+
+

Ovarian
metastasis

Tubal
Positive
Pelvic LN Tumor
metastasis peritoneal cytology metastasis size
+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+
+
+

+

10

+

+

+

+

+

11

+

+

+

+

+

12

+

+

+

+

+

13

+

+

+

+

+

+

+

14

+

+

+

+

+

+

+
+
+

Cell type: endometrioid vs. nonendometrioid; Grade: 2 and 3; DMI: depth of myometrial invasion ≥ 1/2; LVSI: lymphovascular space
invasion; CI: cervical invasion; LN: lymph node; Tumor size: ≥40 mm.

The average number of lymph nodes removed
was 61.1 (range: 27–122). The average number of
pelvic and PA lymph nodes removed was 42.1 (range:
16–81) and 19.2 (range: 10–46), respectively. There
was lymph node metastasis in 32 (21.1%) patients.
Of these patients, 18 had lymph node metastasis in
the PA region. There were 5 (3.3%) patients who had
PA lymph node metastasis and no pelvic lymph node
metastasis, and this group of patients was categorized
as having isolated PA lymph node metastasis.
Except for 2 risk groups (group 10 and 7), more
than 80% of patients carried at least 1 of the risk
factors in the groups (Table 2). In group 10, 52% of
patients carried a risk factor, while in group 7, 69.7%
of patients carried a risk factor.
Univariate analysis revealed that depth of
myometrial invasion, tumor size (cut-off value of <40
mm), presence of LVSI, cervical invasion, peritoneal
spread, and pelvic lymph node metastasis were
determining factors for PA lymph node metastasis
(Table 3). However, it was seen in binary logistic
regression analysis that LVSI and pelvic lymph node
metastasis were independent prognostic factors for
PA lymph node involvement (OR: 6.4, 95% CI: 1.6–
25.8 and OR: 17.5, 95% CI: 5.1–59.5, respectively).

Pelvic lymph node metastasis was an important
factor for predicting PA lymph node status in the
risk modeling system. In groups where pelvic lymph
node metastasis was included in the modeling
system (groups 6, 8, 9, and 10), univariate analysis
showed that for patients carrying at least one risk
factor, PA lymph node involvement was increased
significantly or the increase was at a borderline
level of insignificance (Table 4). In 3 of these groups
(groups 6, 8, and 9), sensitivity and NPV were
100%, while in group 10 these rates were 94% and
98.6%, respectively. However, specificity was 53.7%
in group 10, 32.8% in group 8, and less than 15% in
the other 2 groups. Hence, group 10 had the highest
PPV (21.5%). The reason for this was the number of
factors used to create the group. As the number of
factors increase in the modeling system, sensitivity
and NPV are increased while specificity and PPV are
decreased.
By removing the pelvic lymph node metastasis
risk factor from group 10, the remaining factors
(cell type, LVSI, serosal spread, ovarian metastasis,
and tubal involvement) formed group 11. In group
11, PA lymph node metastasis rate was similar
between patients carrying at least one risk factor and
1261
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Table 2. Characteristics, surgical and pathological factors, and risk groups.
Parameter
Age
Tumor size (mm)
Number of removed total lymph nodes
Number of removed paraaortic lymph nodes
Number of removed pelvic lymph nodes
IA
IB
IC
IIA
IIB
Stage
IIIA
IIIB
IIIC
IVA
IVB
Endometrioid
Clear cell
Cell type
Serous
Mixed type
1
Grade
2
3
Only endometrium
<1/2
Depth of myometrial invasion
≥1/2
Serosal infiltration
Negative
Peritoneal cytology
Positive
Negative
Metastasis to ovary
Positive
Negative
Metastasis to tuba uterina
Positive
Negative
Cervical invasion
Glandular
Stromal
Lymphovascular space
Negative
Positive
invasion
Pelvic and paraaortic lymph node metastasis
Lymph node status
Isolated pelvic lymph node metastasis
Isolated paraaortic lymph node metastasis
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Number of high-risk patients Group 7
Group 8
according to risk groups
Group 9
Group 10
Group 11
Group 12
Group 13
Group 14

1262

Mean (n)

Range (%)

57.5
39.3
61.1
19.2
42.1
9
43
39
1
12
11
1
33
1
1
128
6
8
10
47
63
42
11
58
76
7
143
9
314
18
142
10
120
4
28
89
63
13
14
5
129
139
131
130
132
133
106
109
134
79
129
137
133
139

35–83
0–110
27–122
10–46
16–81
6
28.1
25.5
0.7
7.8
7.2
0.7
21.6
0.7
0.7
84.2
3.9
5.3
6.6
30.9
41.4
27.6
7.2
38.2
50
4.6
94.1
5.9
88.2
11.8
93.4
6.6
79.5
2.6
17.9
58.6
41.4
8.6
9.2
3.3
84.9
88.9
86.2
85.5
86.8
87.5
69.7
71.7
88.2
52
84.9
90.1
87.5
91.4
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Table 3. Univariate analysis of surgical and pathological factors for paraaortic lymph node metastasis.
Parameter
Cell type
Grade
Depth of myometrial invasion
Age

Tumor size

Lymphovascular space invasion
Metastasis to ovary
Metastasis to tuba uterina
Cervical invasion
Peritoneal cytology
Metastasis to pelvic lymph nodes

Metastatic PALN (%)
Endometrioid

12.5

Nonendometrioid*

8.3

1

14.9

2 and 3

10.5

No invasion and <1/2

4.3

≥1/2 and serosal infiltration

18.1

≤57 years

7.5

>57 years

16.7

≤20 mm

9.1

>20 mm

12.6

≤40 mm

5.7

>40 mm

20.3

Negative

3.4

Positive

23.8

Negative

11.2

Positive

16.7

Negative

10.6

Positive

30

Negative

9.2

Positive

19.4

Negative

9.8

Positive

44.4

Negative

4

Positive

48.1

P
0.562
0.436
0.009
0.081
0.580
0.006
<0.0001
0.500
0.066
0.007
0.002
<0.0001

PALN: Paraaortic lymph node; *: clear cell, serous tumor, mixed type.

patients carrying no risk factor (10.7% and 9.5%,
respectively; P = 0.870) (Table 4). These rates were
21.5% and 1.4% in group 10. NPV also fell from
98.6% to 90%. This means that by using the risk
model we missed the metastasis in the PA region in
1.4% of patients in group 10 and 10% of patients in
group 11. When we added tumor size and/or tumor
grade and/or depth of myometrial invasion and/or
cervical invasion (groups 12, 13, and 14), predictive
strength increased when compared with group 11, as
expected. NPV was 100% in 2 of these groups and
94.4% in 1 group. However, in univariate analysis,
there was no difference between patients who were
in the risk group and who were not in terms of PA

lymph node involvement. Additionally, even though
they included more parameters, the strength of
these 3 groups to predict PA region involvement was
significantly lower when compared with group 10.
Although group 7 did not have the pelvic lymph
node involvement risk factor, it was the group that
most closely approached the groups having this
risk factor in terms of predicting PA lymph node
involvement, especially group 8 and group 10.
Though statistically not significant, the PA lymph
node metastasis rate increased from 4.3% to 15.1% in
patients carrying at least 1 of the factors forming this
group. Among all the groups, this group was second
in terms of specificity (32.8%), although it included
1263
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Table 4. Risk model and paraaortic lymph node metastasis.
Risk group
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7
Group 8
Group 9
Group 10
Group 11
Group 12
Group 13
Group 14

PA lymph node
metastasis (%)

Negative

8.7

Positive

12.4

Negative

8.3

Positive

10.7

Negative

5

Positive

11.5

Negative

9.1

Positive

12.3

Negative

5

Positive

12.9

Negative

0

Positive

13.5

Negative

4.3

Positive

15.1

Negative

0

Positive

16.5

Negative

0

Positive

13.4

Negative

1.4

Positive

21.5

Negative

9.5

Positive

10.7

Negative

0

Positive

13.1

Negative

5.3

Positive

12.8

Negative

0

Positive

12.9

P

Sensitivity

Specificity

PPV

NPV

0.621

88.9%

15.7%

12.4%

91.3%

0.795

92.9%

9.2%

10.7%

91.7%

0.382

92.9%

16%

11.5%

95%

0.666

88.9%

14.9%

12.3%

91.3%

0.310

94.4%

14.2%

12.9%

95%

0.068

100%

14.2%

13.5%

100%

0.060

88.9%

32.8%

15.1%

95.7%

0.005

100%

32.1%

16.5%

100%

0.098

100%

13.4%

13.4%

100%

<0.001

94.4%

53.7%

21.5%

98.6%

0.870

85.7%

16%

10.7%

90%

0.135

100%

11.2%

13.1%

100%

0.343

94.4%

13.4%

12.8%

94.7%

0.167

100%

9.7%

12.9%

100%

PA: paraaortic; PPV: positive predictive value; NPV: negative predictive value.

quite a lot of factors (8). However, with this group,
11.1% of patients with PA lymph node metastasis
could not be diagnosed and NPV was 95.7% (Table
4).
The results of group 6 were similar to group
7. In the patients who did not carry factors in this
risk model group, there was no metastasis to the PA
region, and hence sensitivity and NPV were 100%.
The difference between group 6 and group 7 was that
group 6 did not include ovarian metastasis, tubal
1264

involvement, peritoneal spread, or cervical invasion
and did include tumor grade and pelvic lymph node
metastasis.
Group 1 was formed by using cell type, tumor
grade, depth of myometrial invasion, and serosal
involvement. However, results were poor in
predicting metastasis to the PA region. Predictive
strength was not improved even when tumor size
(group 2), adnexal involvement (group 3), cervical
invasion (group 4), or LVSI (group 5) were added. In

A. T. TURAN, B. AYKAN YILDIRIM, I. ÜREYEN, D. HIZLI, M. A. KARALÖK,
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these groups that did not include pelvic lymph node
metastasis as a risk factor, adequate statistical data to
direct treatment could not be obtained.

procedures. When the group 10 model was used, the
number of patients who underwent unnecessary PA
lymphadenectomy fell from 134 to 62, meaning that
it was reduced by more than 50%.

Discussion

Nomura et al. showed in their study that, of the
patients with no metastasis in the pelvic region,
96.4% also had no metastasis in the PA region, and
they suggested that by considering pelvic lymph
node status unnecessary PA lymphadenectomies
could be prevented (10). However, in their study they
found that 48% of patients with pelvic lymph node
metastasis also had metastasis in the PA region. Thus,
according to this study, using only pelvic lymph node
status will lead to unnecessary PA lymphadenectomy
in 52% of patients. It can be seen that even though
the addition of independent prognostic factors could
reduce unnecessary PA lymphadenectomy, it seems
difficult to reach target levels without creating risk
models.

The need for PA lymphadenectomy in the treatment
of endometrial cancer in terms of survival is
controversial. Additionally, the incidence of
finding metastatic lymph nodes in the PA region
in patients undergoing systematic pelvic and PA
lymphadenectomy is not very high. In the present
study, there were tumors in the PA region in 11.9%
of patients undergoing systematic lymphadenectomy
up to the level of the renal vein. Hence, PA
lymphadenectomy was an unnecessary procedure in
nearly 90% of these patients. This high rate can be
reduced by creating risk groups and thus morbidity
associated with this procedure can be prevented.
Isolated PA lymph node metastasis varies in the
literature by up to a rate of 8% (6,8,10–14). In the
current study the rate of isolated PA lymph node
metastasis was 3.3%. Furthermore, in almost half of
the patients with pelvic lymph node metastasis there
was paraaortic lymph node metastasis. Therefore, the
existence of pelvic lymph node status as a risk factor
in the groups created in this study was important
in determining the strength of groups in terms of
predicting PA lymph node metastasis. Group 10
especially was capable of directing treatment by
determining the need for PA lymphadenectomy. In
univariate analysis, whether the patient was in the risk
group or not was an important factor in determining
PA region involvement, and the metastasis rate to this
region increased from 1.4% to 21.5% if the patient
was in this group. By using this risk model, 94.4% of
patients with PA lymph node metastasis and 53.7% of
patients who did not have metastasis were diagnosed
correctly. According to the group 10 model, among
‘not high-risk’ patients, only 1.4% had PA lymph node
metastasis. Another difference in this group was that
the number of patients considered as being high-risk
was low (52% of all patients). In the other groups, the
percentage of patients considered as being high-risk
was greater than 80% of all patients studied. Hence,
only group 10 was appropriate for the purpose of
the study, with the ability to significantly reduce
the number of unnecessary PA lymphadenectomy

Tanaka et al. questioned the need for PA
lymphadenectomy by considering external iliac and
common iliac lymph node status, taking into account
the lymphatic spread pattern of the tumor (9). The
sensitivity and specificity of this parameter was
90% and 96.7%, respectively. This meant that 10%
of patients with PA lymph node metastasis could be
missed; furthermore, the number of lymph nodes
removed was not mentioned in the study. Mariani
et al., in their study focusing on lymphatic spread of
endometrial cancer, found that obturator lymph node
status was more valuable than iliac region lymph
node status in determining PA lymph node status
(17). There was PA lymph node metastasis in 64% of
patients with obturator lymph node metastasis and
23% of patients with iliac lymph node metastasis (P
= 0.01).
Similarly, McMeekin et al. showed that common
iliac region status and PA lymph node status were
not associated (18). In their study, they observed
that 57% of the patients with PA lymph node
metastasis did not have tumors in the common iliac
region. Unlike cervical cancer, lymphatic spread in
endometrial carcinoma does not occur by regional
order. The reason for this is the variability of the
location of tumor and markedly frequent occurrence
of adnexal metastasis in endometrial carcinoma.
Hence, lymphatic chain order is not associated
1265
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with predictable lymphatic spread in endometrial
carcinoma.

in group 10, where it was almost twice (21.5%) the
classical practice.

The low specificity and PPV obtained in the
current study may seem to be disadvantages.
However, the probability of a model that is composed
of a few prognostic factors to detect nonexistence
would be low since the aim is to detect the existence
at a high rate, and so the PPV value will decrease. On
the other hand, today we perform systematic bilateral
pelvic and PA lymphadenectomy from the renal vein
down to the circumflex iliac vein in cases with cell
types other than endometrioid adenocarcinoma,
tumor grade 2 or 3, ≥1/2 myometrial invasion, and
tumor size greater than 2 cm, which are detected in
frozen section analysis for the staging of endometrial
carcinoma. PA lymph node metastasis is detected in
11.9% of these cases. This means that the PPV of our
classical practice in detecting spread to the PA region
was 11.9%. Therefore, although the rates that were
obtained with the risk models seemed low, they were
actually better than our classical practice. Especially

As a result, with the help of risk models, PA
lymph node status can be more clearly identified
and unnecessary dissection of the PA region and
associated morbidity can be prevented. These
models should also be utilizable. In our institution,
accuracy of frozen section analysis for myometrial
invasion and grade in endometrial carcinoma is
quite high and similar to that in the literature (85%
and 89%, respectively; unpublished data). In the
present study, the factors constituting group 10 (cell
type, LVSI, serosal invasion, adnexal metastasis,
and pelvic lymph node metastasis) can be identified
easily with frozen section pathology. By the help
of this group, metastasis to the PA region can be
predicted correctly in most cases and the number of
PA lymphadenectomies can be significantly reduced.
However, for defining risk groups more clearly and
for standardization of treatment, there is still the need
for further prospective studies with larger numbers
of patients.
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